Dmitry R. Gumerov

847 citations

24 papers · 576 indexed · h-index 12

Molecular Biology
Spectroscopy top 5%
Oncology
Radiology, Nuclear Medicine and Imaging top 10%
Hematology

Co-authors: Igor A. Kaltashov Anne B. Mason Mingxuan Zhang J. Paul Speir András Dobó Jayanti R. Patel Ryan M. Danell Ivan Rusyn
Topics: HER2/EGFR in Cancer Research (14 papers)Monoclonal and Polyclonal Antibodies Research (12 papers)Radiopharmaceutical Chemistry and Applications (7 papers)
Cited by: Spectroscopy Hematology Radiology, Nuclear Medicine and Imaging
Journals: Analytical Chemistry Biochemistry Cancer Research
Partner nations: United States Canada Germany

In The Last Decade

Dmitry R. Gumerov

24 papers receiving 552 citations

Peers

Countries citing papers authored by Dmitry R. Gumerov

Since Specialization

Citations

This map shows the geographic impact of Dmitry R. Gumerov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitry R. Gumerov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitry R. Gumerov more than expected).

Fields of papers citing papers by Dmitry R. Gumerov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dmitry R. Gumerov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitry R. Gumerov. The network helps show where Dmitry R. Gumerov may publish in the future.

Co-authorship network of co-authors of Dmitry R. Gumerov

This figure shows the co-authorship network connecting the top 25 collaborators of Dmitry R. Gumerov. A scholar is included among the top collaborators of Dmitry R. Gumerov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dmitry R. Gumerov. Dmitry R. Gumerov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates 2022 ·Bioorganic & Medicinal Chemistry Letters ·Joshua D. Thomas,(unknown),Mao Yin,Natalya D. Bodyak,Dmitry R. Gumerov,(unknown),(unknown),Brian Jones,Marina Protopopova,LiuLiang Qin,(unknown),Damon R. Demady,Timothy B. Lowinger	3
2	Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry 2020 ·UNC Libraries ·Cameron O. Scarlett,Steven H. Zeisel,Jun Han,Jayanti R. Patel,(unknown),Christoph H. Borchers,Carol E. Parker,Dmitry R. Gumerov,Ryan M. Danell,Ivan Rusyn	1
3	Abstract 754: Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect 2018 ·Cancer Research ·Susan M. Clardy,(unknown),Mao Yin,Dmitry R. Gumerov,Ling Xu,Elena Ter‐Ovanesyan,(unknown),(unknown),Marina Protopopova,Qingxiu Zhang,Natalya D. Bodyak,Marc Damelin,David H. Lee,Donald A. Bergstrom,Timothy B. Lowinger	8
4	MA09.10 A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC 2017 ·Journal of Thoracic Oncology ·Donald A. Bergstrom,Natalya D. Bodyak,(unknown),Laura L. Poling,Mao Yin,Marina Protopopova,(unknown),LiuLiang Qin,Dmitry R. Gumerov,Elena Ter‐Ovanesyan,Rebecca Mosher,Timothy B. Lowinger	3
5	Abstract 48: Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate 2017 ·Cancer Research ·(unknown),Dmitry R. Gumerov,Elena Ter‐Ovanesyan,Patrick R. Conlon,Michael J. DeVit,(unknown),Natalya D. Bodyak,Timothy B. Lowinger,Donald A. Bergstrom	11
6	Abstract 596: Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC) 2016 ·Cancer Research ·(unknown),(unknown),Dmitry R. Gumerov,Dongmei Xiao,Joshua D. Thomas,Laura L. Poling,LiuLiang Qin,Mao Yin,Michael J. DeVit,Peter U. Park,Winnie Lee,Bianka Prinz,Donald A. Bergstrom,Timothy B. Lowinger	2
7	Abstract 1194: Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models 2016 ·Cancer Research ·Natalya D. Bodyak,(unknown),Mao Yin,Dmitry R. Gumerov,(unknown),Patrick R. Conlon,(unknown),(unknown),(unknown),Elena Ter‐Ovanesyan,Peter U. Park,Laura L. Poling,Winnie Lee,Michael J. DeVit,Dongmei Xiao,LiuLiang Qin,Timothy B. Lowinger,Donald A. Bergstrom	5
8	A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy 2015 ·Cancer Research ·(unknown),Mao Yin,Natalya D. Bodyak,(unknown),Joshua D. Thomas,Charles E. Hammond,LiuLiang Qin,Bangmin Zhu,Dmitry R. Gumerov,Elena Ter‐Ovanesyan,(unknown),Timothy B. Lowinger	73
9	Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors 2015 ·Cancer Research ·Donald A. Bergstrom,Natalya D. Bodyak,(unknown),Peter U. Park,Michael J. DeVit,Mao Yin,Laura L. Poling,Joshua D. Thomas,Dmitry R. Gumerov,Dongmei Xiao,Elena Ter‐Ovanesyan,LiuLiang Qin,(unknown),(unknown),Timothy B. Lowinger	12
10	Abstract 1693: ASN004, a novel 5T4-targeted Dolaflexin™ antibody drug conjugate, causes complete regression in multiple solid tumor models 2015 ·Cancer Research ·Roger A. Smith,Nitin K. Damle,Sanjeeva Reddy,(unknown),Natalya D. Bodyak,Mao Yin,Dmitry R. Gumerov,Elena Ter‐Ovanesyan,Qin Liu,Peter U. Park,Timothy B. Lowinger,(unknown)	2
11	Abstract 2645: Advantages of polyacetal polymer-based ADCs: Application to low expression targets 2014 ·Cancer Research ·(unknown),Natalya D. Bodyak,Mao Yin,Joshua D. Thomas,Patrick R. Conlon,(unknown),(unknown),LiuLiang Qin,Dmitry R. Gumerov,(unknown),(unknown),(unknown),(unknown),Michael J. DeVit,Laura L. Poling,Peter U. Park,Timothy B. Lowinger	1
12	Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity. 2013 ·Molecular Cancer Therapeutics ·Joshua D. Thomas,(unknown),Natalya D. Bodyak,Mao Yin,Patrick R. Conlon,(unknown),(unknown),Liu Q,Dmitry R. Gumerov,(unknown),Michael J. DeVit,Laura L. Poling,Peter U. Park,Timothy B. Lowinger	1
13	Transferrin as a model system for method development to study structure, dynamics and interactions of metalloproteins using mass spectrometry 2011 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Igor A. Kaltashov,Cedric E. Bobst,Mingxuan Zhang,Rachael Leverence,Dmitry R. Gumerov	24
14	Electron transfer dissociation in the hexapole collision cell of a hybrid quadrupole‐hexapole Fourier transform ion cyclotron resonance mass spectrometer 2008 ·Rapid Communications in Mass Spectrometry ·Desmond A. Kaplan,Ralf Hartmer,J. Paul Speir,Carsten Stoermer,Dmitry R. Gumerov,Michael L. Easterling,(unknown),Taeman Kim,Frank H. Laukien,Melvin A. Park	49
15	Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry 2008 ·Metabolomics ·Jun Han,Ryan M. Danell,Jayanti R. Patel,Dmitry R. Gumerov,Cameron O. Scarlett,J. Paul Speir,Carol E. Parker,Ivan Rusyn,Steven H. Zeisel,Christoph H. Borchers	114
16	Indirect detection of protein-Metal binding: Interaction of serum transferrin with In³⁺ and Bi³⁺ 2004 ·Journal of the American Society for Mass Spectrometry ·Mingxuan Zhang,Dmitry R. Gumerov,Igor A. Kaltashov,Anne B. Mason	43
17	Interlobe Communication in Human Serum Transferrin: Metal Binding and Conformational Dynamics Investigated by Electrospray Ionization Mass Spectrometry 2003 ·Biochemistry ·Dmitry R. Gumerov,Anne B. Mason,Igor A. Kaltashov	37
18	Protein—Ion Charge-State Distributions in Electrospray Ionization Mass Spectrometry: Distinguishing Conformational Contributions from Masking Effects 2002 ·European Journal of Mass Spectrometry ·Dmitry R. Gumerov,András Dobó,Igor A. Kaltashov	43
19	Differential Effect of a His Tag at the N- and C-Termini: Functional Studies with Recombinant Human Serum Transferrin 2002 ·Biochemistry ·Anne B. Mason,Qing‐Yu He,Peter J. Halbrooks,Stephen J. Everse,Dmitry R. Gumerov,Igor A. Kaltashov,Valerie C. Smith,Jeff Hewitt,Ross T. A. MacGillivray	51
20	Expression, Purification, and Characterization of Recombinant Nonglycosylated Human Serum Transferrin Containing a C-Terminal Hexahistidine Tag 2001 ·Protein Expression and Purification ·Anne B. Mason,Qing‐Yu He,Ty E. Adams,Dmitry R. Gumerov,Igor A. Kaltashov,(unknown),Ross T. A. MacGillivray	33

About Dmitry R. Gumerov

Dmitry R. Gumerov is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Hematology, having authored 24 papers that have together received 576 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). The work is most often cited by research in Spectroscopy (198 citations), Hematology (68 citations) and Radiology, Nuclear Medicine and Imaging (123 citations). Dmitry R. Gumerov has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Igor A. Kaltashov, Anne B. Mason, Mingxuan Zhang, J. Paul Speir, András Dobó, Jayanti R. Patel, Ryan M. Danell, Ivan Rusyn, Carol E. Parker and Cameron O. Scarlett. Their work appears in journals such as Analytical Chemistry, Biochemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact